Last updated on December 2018

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer


Brief description of study

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Clinical Study Identifier: NCT02857270

Contact Investigators or Research Sites near you

Start Over

Manish Rajni Patel

Florida Cancer Specialists
Sarasota, FL United States
  Connect »

Ryan Sullivan

Massachusetts General Hospital
Boston, MA United States
  Connect »

SMO Sarah Cannon Research Inst.

Sarah Cannon Cancer Center
Nashville, TN United States
  Connect »

Johanna Chock Bendell

Tennessee Oncology PLLC
Nashville, TN United States
  Connect »

Shubham Pant

University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Stephen V Liu

Georgetown University Medical Center
Washington, WA United States
  Connect »

Konstantin Dragnev

Dartmouth Hitchcock Medical Center
Lebanon, NH United States
  Connect »

Timothy F Burns

UPMC Hillman Cancer Center
Pittsburgh, PA United States
  Connect »

Anthony Joshua

St Vincent's Hospital
Sydney, Australia
  Connect »

Michael J Millward

Linear Clinical Research Ltd
Nedlands, Australia
  Connect »

Antoine Hollebecque

Gustave Roussy
Villejuif Cedex, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.